Biohaven Pharmaceutical Holding Gross Margin 2016-2022 | BHVN
Current and historical gross margin for Biohaven Pharmaceutical Holding (BHVN) over the last 10 years. The current gross profit margin for Biohaven Pharmaceutical Holding as of March 31, 2022 is %.
| Biohaven Pharmaceutical Holding Gross Margin Historical Data |
| Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
| 2022-03-31 |
$0.74B |
$0.63B |
85.77% |
| 2021-12-31 |
$0.46B |
$0.37B |
80.13% |
| 2021-09-30 |
$0.31B |
$0.24B |
78.57% |
| 2021-06-30 |
$0.19B |
$0.15B |
76.32% |
| 2021-03-31 |
$0.11B |
$0.08B |
71.03% |
| 2020-12-31 |
$0.06B |
$0.05B |
71.88% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$9.996B |
$0.463B |
|
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
|
